Skip to main content

Pennsaid - Enhanced & Essential

Commercial Policy
Version Date: December 2024

Utilization Management Policy Name: Pennsaid - Enhanced & Essential

 

Restricted Product(s):

Restriction applies to brand and generic products

  • Pennsaid (diclofenac sodium topical solution 2%)
  • Diclofenac sodium topical solution 1.5%

 

FDA Approved Use:

  • For the treatment of osteoarthritis pain of the knee(s).

 

Criteria for Approval of Restricted Product(s):

 

    1. The patient is 18 years of age and older; AND

    2. The patient has a diagnosis of osteoarthritis of the knee; AND

    3. ONE of the following:

        a. The patient had a therapeutic failure with a one-week trial of an oral NSAID for this condition; OR

        b. The patient has had intolerable side effects or contraindications to oral NSAIDs; OR

        c. The patient is at high risk of gastric bleeding with oral NSAIDs; OR

        d. The patient cannot swallow solid oral dosage forms and is not currently taking any solid oral dosage form; AND

    4. The patient is not using with an oral NSAID (includes COX-2 inhibitors) prescribed for the same condition; AND

    5. The patient has tried and failed or has a contraindication/intolerance to diclofenac 1% topical gel (prescription or OTC); AND

    6. For formularies that exclude (non-formulary) the requested medication, Non-formulary Exception Criteria applies.

 

Duration of Approval:

365 days (1 year)

 

References:

All information referenced is from FDA package insert unless otherwise noted below.

 

Policy Implementation/Update Information:

Criteria and treatment protocols are reviewed annually by the Blue Cross NC P&T Committee, regardless of change. This policy is reviewed in Q4 annually.

 

December 2024: Criteria update: removed brand Pennsaid 1.5% (obsolete). Restriction still applies to generic.
May 2022: Criteria update: Duration of approval changed to 1 year.
January 2021: Criteria change: Require t/f diclofenac 1% topical gel (prescription or OTC).
October 2019: Criteria update: Reformatted criteria. Changed duration of approval to 3 years.
October 2018: Annual review; No change.
January 2017: Nonformulary verbiage added.
October 2016: Annual review; No change.
October 2015: Annual review; No change.
August 2014: Historical revision.